by Barry | Jan 23, 2023 | Press Releases
In early December, VMT-α-NET, the Company’s lead drug for the treatment of neuroendocrine tumors was administered to patients in India on a compassionate use basis, independent of a planned US trial No acute adverse reactions were observed in the first 10...
by Barry | Oct 18, 2022 | Press Releases
RICHLAND, Wash. & CORALVILLE, Iowa–(BUSINESS WIRE)–Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision...
by Barry | Oct 11, 2022 | Press Releases
SBIR Phase II Grants bring the cumulative grant total to approximately $17 million from the National Institutes of Health and National Cancer InstituteCORALVILLE, IA / October 11, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the...
by Barry | Oct 4, 2022 | Press Releases
Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugsCORALVILLE, IA / October 4, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the...
by Barry | Oct 3, 2022 | Press Releases
CORALVILLE, IA / October 3, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging...
Recent Comments